NASDAQ:ICCCImmuCell Stock Price, Forecast & News

$4.56

+0.10 (+2.24 %)

(As of 06/3/2020 03:20 PM ET)

Add

Compare

Today's Range

$4.56

Now: $4.56▼

$4.60

50-Day Range

$4.02

MA: $4.31▼

$4.68

52-Week Range

$3.70

Now: $4.56▼

$8.13

Volume688 shs

Average Volume47,039 shs

Market Capitalization$32.88 million

P/E RatioN/A

Dividend YieldN/A

Beta1.43

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for ImmuCell.

2.9 Community Rank

Outperform Votes
ImmuCell has received 118 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ImmuCell has received 84 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ImmuCell has received 58.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote “Outperform” if you believe ICCC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ImmuCell does not currently pay a dividend.
Dividend Growth
ImmuCell does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmuCell insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 14.60% of the stock of ImmuCell is held by insiders.
Percentage Held by Institutions
Only 14.04% of the stock of ImmuCell is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of ImmuCell is -19.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmuCell is -19.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ImmuCell has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.18 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ICCC

Previous Symbol

CUSIPN/A

CIK811641

Webwww.immucell.com

Phone207-878-2770

Debt

Debt-to-Equity Ratio0.28

Current Ratio5.88

Quick Ratio5.02

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.72 million

Price / Sales2.40

Cash Flow$0.14 per share

Price / Cash Flow32.11

Book Value$4.02 per share

Price / Book1.13

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-1,300,000.00

Net Margins-10.98%

Return on Equity-5.35%

Return on Assets-3.98%

Miscellaneous

Employees47

Outstanding Shares7,210,000

Market Cap$32.88 million

Next Earnings Date8/10/2020 (Estimated)

OptionableNot Optionable

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

How has ImmuCell's stock been impacted by COVID-19 (Coronavirus)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICCC shares have increased by 6.0% and is now trading at $4.56. View which stocks have been most impacted by Coronavirus.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for ImmuCell.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. The biotechnology company had revenue of $4.91 million for the quarter. ImmuCell had a negative net margin of 10.98% and a negative return on equity of 5.35%. View ImmuCell's earnings history.

Has ImmuCell been receiving favorable news coverage?

News stories about ICCC stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ImmuCell earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutImmuCell.

Are investors shorting ImmuCell?

ImmuCell saw a drop in short interest in May. As of May 15th, there was short interest totaling 22,200 shares, a drop of 31.9% from the April 30th total of 32,600 shares. Based on an average daily trading volume, of 29,500 shares, the short-interest ratio is currently 0.8 days. Approximately 0.4% of the shares of the stock are sold short. View ImmuCell's Current Options Chain.

Who are some of ImmuCell's key competitors?

Some companies that are related to ImmuCell include Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), GeneNews (GNWSF), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ). View all competitors.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Protalix Biotherapeutics (PLX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Fate Therapeutics (FATE) and Gilead Sciences (GILD).

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:

Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (5.36%) and BlackRock Inc. (0.18%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche. View institutional ownership trends for ImmuCell.

Which major investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP. View insider buying and selling activity for ImmuCell.

Which major investors are buying ImmuCell stock?

ICCC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche. View insider buying and selling activity for ImmuCell.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $4.56.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $32.88 million and generates $13.72 million in revenue each year. ImmuCell employs 47 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff